
|Articles|June 1, 2005
Squalamine lactate preserves vision in phase II trial
Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Rayner’s RayOne EMV Toric intraocular lens
2
Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA
3
NeuroOp Guru: When proptosis isn’t thyroid eye disease
4
Ophthalmic innovation by the decades: The 1980s and 1990s
5